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ABSTRACT 
ADRIAMYCIN NEPHROTOXICITY IS REDUCED BY MET ALLOTHIONEIN 
OVER-EXPRESSION AND KIDNEY GENE EXPRESSION IS MODIFIED BY 
DIABETES IN THE OVE26 DIABETIC MODEL 
Lu Yang 
December 3,2010 
This thesis is divided into two parts below. 
Part I 
Adriamycin (ADR) can produce nephrotoxicity in rodents. The underlying mechanism 
may relate to ADR induced oxidative stress. In this study, we used transgenic mice 
(NMT3), which over-expressed the antioxidant protein metallothionein (MT) in 
podocytes, to study MT's protective potential on ADR nephrotoxicity. Urine and kidney 
samples were collected from control and transgenic mice at multiple time points after 
ADR injection, whose results showed that MT transgene alleviated ADR damage by 
reducing albuminuria, decreasing podocyte loss and protecting podocyte ultra-structure. 
Part II 
OVE26 mice are a good model of severe diabetic nephropathy (DN). We examined 
progressive changes in renal gene and protein expression in OVE26 and control mice. 
Inflammatory genes were most affected by diabetes, especially at oldest ages tested, 
iv 
which correlated with increasingly severe albuminuria. Vitamin D metabolism was also 
changed by DN. 
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CHAPTER I 
METALLOTHIONEIN OVER-EXPRESSION IN PODOCYTES REDUCES 
ADRIAMYCIN NEPHROTOXICITY 
INTRODUCTION 
Adriamycin Induced Nephrotoxicity and Potential Mechanisms 
Adriamycin (ADR) is commonly used to treat leukemia, lymphoma and 
other cancers. However, clinical use of ADR is limited due to its toxicity to kidney, 
heart and other organs. Its complex cytotoxic mechanisms [1] are known to include 
enzyme inhibition, DNA intercalation, reactive oxygen species generation [2] and 
inductions of apoptosis. ADR-induced nephropathy has been well characterized in 
rodents and demonstrated to include albuminuria, impaired glomerular function, 
glomerulosclerosis, morphological changes and other features[3,4]. In mice ADR 
nephropathy varies among strains, with BALB/C mice being highly susceptible while 
C57BLl6J mice and most other strains are resistant [5]. 
Reactive oxygen species (ROS) are thought to be involved in the mechanism 
of ADR-induced kidney damage. ADR undergoes one-electron reduction catalyzed by 
flavin-containing enzymes [6] such as NADPH-cytochrome-P-450 reductase [7]. This 
reduction generates a semiquinone free-radical. In the presence of molecular oxygen, 
the semiquinone reduces oxygen to superoxide and regenerates intact ADR. The ADR 
semiquinone can also react with hydrogen peroxide to yield hydroxyl radical [8]. These 
toxic ROS react with cellular molecules, including nucleic acids, protein and lipids, 
causing cell damage. Most evidence for this free radical hypothesis comes from in vitro 
studies on cell lines, including reports that: (1) ADR increases ROS levels and lipid 
peroxidation [9] and (2) the finding that free radical scavengers such as N-acetylcysteine 
[10], vitamin E [11] and superoxide dismutase [11] decrease the severity of 
ADR-induced damage. The free radical mechanism of ADR toxicity has been shown to 
apply to kidney cells. In cultured glomerular epithelial cells, ADR increased ROS 
production and produced cytoxicity [12]. ADR damage to cultured glomerular 
epithelial cells could be reduced by prior incubation with an ROS scavenger [12]. 
Podocytes and Glomeruli 
The nephron is the basic structure and functional unit of kidney. Each normal 
human kidney contains approximately one million nephrons, which help regulate the 
amount of water, salts, glucose, urea and other minerals in the human body. Each nephron 
consists of a filtering component (renal corpuscle) and a tubule that functions in 
reabsorption and secretion (renal tubule) (Figure IA). The glomerulus surrounded by 
Bowman's capsule, constitutes a renal corpuscle and is essential for the filtering function 
of the nephron (Figure IB). It is a capillary tuft resembling a twisted mass of tiny tubes 
through which the blood passes, exchanges water and waste, then has passed out of the 
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Bowman's capsule as urine. Injury to gomeruli can interfere with its normal function and 
cause protein leakage into urine. 
Glomeruli contain several cell types, endothelial cells, mesangial cells and 
podocyte cells. Podocytes surround the glomerular capillaries and are a component of the 
glomerular filtration barrier which prevents leakage of protein in the urine. Podocytes are 
needed to maintain a functional glomerular basement membrane [13] and healthy 
glomerular capillaries [14]. Destruction ofpodocytes can lead to massive proteinuria, 
which shows up in many nephropathy models including ADR [15] and diabetic 
nephropathy (DN) [16,17]. Therefore many studies have focused on podocytes damage 
to investigate their role in causing nephropathy. 
Adriamycin Damage to Podocytes 
In rodents model, ADR is rapidly cleared from the plasma after intravenous 
injection, deposited in tissue, mainly in kidney, which probably contributes to its great 
nephrotoxicity [18]. As described at the beginning of this Introduction, ADR promotes 
free radical generation. Animal studies had indicated that adriamycin induced 
nephrotoxicity is related to free radical generation and lipid peroxidation [19]. 
Supplement with antioxidants or increasing renal antioxidant levels such as GSH, could 
protect against adriamycin induced renal injury [10,11,20]. 
Adriamycin could produce toxic effect to podocytes [21]. There are many in 
vitro and in vivo results demonstrating that Adriamycin treatment caused podocyte 
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apoptosis [22], podocyte cytoskeleton structural reorganization [15] and loss of podocyte 
foot process [23]. 
We proposed that if podocyte damage of Adriamycin is direct and related to free 
radical formation then supplementation of podocyte with an antioxidant may reduce 
Adriamycin toxicity in kidney. 
Function of Metallothionein as an Antioxidant 
Metallothionein (MT) is a low molecular weight (mammalian form is 
6000-7000 Da), cysteine-rich, metal-binding (Zinc, Copper, Cadmium, Mercury, etc.) 
and highly inducible protein [24]. The induction ofMT by oxidative stress has led to 
the speculation that MT might play roles in scavenging free radicals. There are many in 
vitro experiments demonstrating that MT can scavenge superoxide anions or hydroxyl 
radicals [25], phenoxyl radicals [26] and nitric oxide [27]. In yeast, increased MT levels 
are able to functionally substitute for antioxidant functions of copper/zinc superoxide 
dismutase [28]. During in vivo animal studies, MT is capable of scavenging many 
different types of ROS in pancreatic islets based on many laboratories previous findings 
[29,30]. MT also attenuates the cardiotoxicity of doxorubicin mainly due to its 
free-radical-scavenging properties [31]. Further, acute hepatic toxicity and hepatic 
oxidative stress have been reduced in MT transgenic mice. Conversely, increased 
intracellular oxidation and sensitivity to oxides has been observed in cells derived from 
mice lacking functional MT genes [32,33]. 
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Mechanisms underlying the antioxidant function ofMT are controversial. 
Some think that MT might function as an expendable target for oxidants due to its 
enriched cysteine residue structure. This was verified by Quesada and co-workers 
[34]showing that the sulfhydryl groups ofMT isolated from HL-60 cells were oxidized 
by exposure of cells to H20 2. 
Other investigators have suggested different antioxidant mechanisms for 
MT. The alternative proposed mechanisms underlying MT function might include its 
ability to complex transition metal (Cu) [35], or altered Zinc and copper homeostasis [32]. 
Thomas et al reported that in the erythrocyte ghosts system, the primary determinant of 
MT protection from oxidants appeared to be metal dependent [36]. In addition, Zhou et 
al have shown that Zn protects from several organ injuries including alcoholic hepatic 
damage [37] independently ofMT. 
Overall, whether MT functions as a direct antioxidant due to its 
cysteine-enriched structure, or as an antioxidant indirectly by affecting two important 
metals, Zn and Cu, or other possible mechanisms including conjunction with GSH [38,39] 
is still uncertain. However, based on a number of in vitro and in vivo experiments, the 
antioxidant role of MT is well documented. 
Prior Development and Studies of 
Transgenic Mice Over-expressing MT in Podocytes 
5 
Our lab developed a transgenic line of mice (called NMT mice) with the 
antioxidant protein metallothionein (MT) over-expressed in podocytes [40]. We 
demonstrated that this line of mice was significantly protected from diabetic nephropathy. 
In severely diabetic mice at 4 month age, MT over-expression produced a 70-90% 
reduction in 24 hour albumin excretion and also reduced podocyte damage, as indicated 
by more podocytes per glomerulus and a higher density of podocyte foot processes. 
Since MT possesses potent antioxidant action and ROS are thought to be the 
cause of ADR induced kidney damage, we elected to test whether MT could also reduce 
ADR nephrotoxicity. MT protects from ROS due to its very high thiol content. Our 
prior work in pancreatic beta cells [30] and cardiomyocytes [41] indicated that transgenic 
over-expression ofMT scavenges a broad range ofROS. Importantly, we previously 
demonstrated that cardiac over-expression ofMT protected the heart against 
ADR-induced cardiotoxicity [42]. These results indicated that MT would be a good 
antioxidant to protect against ADR nephropathy. 
Podocytes are a glomerular cell-type sensitive to ADR cytotoxicity [15] and 
podocytes are critical to maintaining normal glomerular structure and function. 
Therefore, in this project we tested whether targeted over-expression ofMT protein in 
podocytes could both reduce podocyte damage and decrease ADR nephropathy. 
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METHODS AND MATERIALS 
Animals 
Our lab produced transgenic mice with podocyte-specific over-expression of 
MT on the FVB background. The transgene designated Nmt contained 8300 bp of the 
podocyte-specific mouse nephrin promoter (Dr Moeller, University of Michigan) ligated 
to a 2400 bp fragment containing the human MTII gene [29]. Podocyte-specific 
over-expression of MT was evaluated by immunohistochemistry and western blotting of 
glomerular protein with an MT-specific antibody. All mice were housed in ventilated 
cages at the University of Louisville Research Resource Center with free access to water 
and standard mice diet. All animal procedures adhered to the guidelines of the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the University of Louisville Institutional Animal Care and Use Committee. 
Chemicals 
Adriamycin (Doxorubicin hydrochloride, 2mg/ml) was purchased from 
Sigma-Aldrich (St. Louis, MO). WT -1 antibody (1 :50; rabbit polyclonal) was purchase 
from Santa Cruz Biotechnology (Santa Cruz, CA). MT antibody (1:40; mouse 
monoclonal) was purchased from DAKO (Glostrup, Denmark). Oregon Green 488 
phalloidin was purchased from Invitrogen (Carlsbad, CA). Urine albumin ELISA kit 
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was purchased from Bethyl Laboratories (Montgomery, TX). All other chemicals and 
solvents were of analytical grade. 
Experimental protocol 
To induce adriamycin (ADR) nephropathy on FVB background mice, the 
first step was to choose an appropriate ADR dose because ADR's effect is different from 
strain to strain. We tested three doses, 9mg/kg body weight, 11 mg/kg body weight and 
13mg/kg body weight. These tests indicated that 9mg and 11 mg could induce 
microalbuminuria on the FVB strain whereas the 13mg dose killed some mice right after 
injection. Therefore we chose the Ilmg/body weight dosage for our experiments. 
Two groups of mice, the FVB control group and the NMT transgenic group 
(15 male in each group), received the Ilmg/kg body weight dosage of ADR through tail 
vein injection. Twenty-four hour urine albumin excretion was measured and compared 
between the two groups at fixed time points; 5days, 1 week, 2 weeks, 3 weeks and 
4weeks. Four mice in both groups were sacrificed at the 5th day after ADR treatment for 
renal pathology and immunohistochemistry studies. For control samples, we sacrificed 
four untreated FVB mice and four untreated NMT transgenic mice. 
Tail Vein injection of ADR 
Prepares the Adriamycin solution in saline solution to a final concentration 
of 2mg/ml. The mouse is placed into the barrel of a mouse restrainer and the restrainer 
is adjusted to make sure that mouse cannot move. The mouse tail is placed into a 50°C 
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water bath to make it swollen. After 2~3 min, one of the two lateral veins of the tail is 
located and a syringe needle is inserted into the vein. The required amount of dosage is 
smoothly injected. 
Urine collection and measurement of albuminuria 
Twenty-four hour urine was collected using mouse metabolic cages at 
selected time points after ADR injection (5days, 1 week, 2 weeks, 3 weeks and 4 weeks). 
Mouse urine volume was increased by including 10% Glucema (Abbott Laboratories) in 
the drinking water. This produces a larger urine volume and allows for a more complete 
recovery of24 hour urine samples. 
Urine albumin was measured by commercial ELISA kit from Bethyl 
company. Urine albumin levels were also assayed before ADR injection as the zero day 
control point, from which we can see how much effect ADR has on urine albumin 
excretion. 
F-actin immunofluorescence assay of hydrogen peroxide injury to podocytes 
Cultured glomeruli were used in order to directly expose podocytes to 
oxidative injury and to be able to identify podocytes. In brief, cultured glomeruli were 
obtained by the following procedure: Glomeruli were purified from normal or transgenic 
mice by the Dynal beads perfusion procedure [43]. Glomeruli were then plated on glass 
coverslips in DMEM/F12 media for 4-5 days at 37°C in 95% air, 5% C02. During this 
period podocytes extended out as mono layers from the centre of the glomerular tuft. 
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After 16 hours treatment with 880uM hydrogen peroxide cells were fixed in 3.7% 
formaldehyde in sodium phosphate buffer for 10 min at room temperature and then 
permeabilized with 0.1 % Triton X-lOO in sodium phosphate buffer for 3-5 min. 
Podocytes were stained with antibody to the podocyte-specific marker WTl (1 :50; rabbit 
polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA). F-actin was detected using 
Oregon Green 488 phalloidin (Invitrogen, Carlsbad, CA) diluted 1 :40 in sodium 
phosphate buffer. The mounted cells were then photographed on a Nikon E600 
fluorescent microscope. Images were rated by a blind observer for location and 
sharpness ofF-actin filaments. This part of work was done by shirong zheng in Dr Paul. 
N Epstein's lab. 
Histopathological studies 
Kidneys removed from anesthetized mice were immediately cut in half and 
fixed in 10% formaldehyde in 0.1 M PBS (pH 7.2), and then transferred to 70% ethanol 
after 24 hours. The kidney tissue was then dehydrated in ascending concentrations of 
isopropanol and finally cleared in xylene and then embedded in paraffin. Blocks were 
sectioned at 5 ~m thickness. Prior to histochemical staining sections were cleared in 
xylene and rehydrated. Sections stained with hemotoxylin and eosin (HE), periodic acid 
Schiff (PAS) and trichrome were used to evaluate the general structural changes in 
glomeruli and tubules and for calculation of glomerular volume. 
Stained sections were viewed under a light microscope and images were 
recorded at 400X magnification. The cross-sectional area of the glomerular tuft (AG) 
was determined from outlines of the tuft using the program Adobe Photoshop 7.0. 
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Glomerular volume (VG) was calculated from the cross-sectional area using the formula 
VG = Wk (AG)3/2, where p= 1.38 is the shape coefficient for a sphere and k=1.1 is the 
size distribution coefficient [44,45]. 
Immunohistochemistry analysis 
Formalin-fixed-paraffin-embedded sections were stained with antibody to 
the podocyte specific marker WT -1 (1 :50; rabbit polyclonal, Santa Cruz Biotechnology, 
Santa Cruz, CA) and for MT (1 :40, mouse, monoclonal, DAKO). To quantify podocyte 
numbers, on each section we picked 20 glomeruli randomly and counted the WT-l 
positive cells under the light microscope. Podocyte staining and quantification were 
performed on 4 groups of mice: FVB mice 5 days after ADR-treatment, NMT mice 5 
days after ADR-treatment, FVB mice without ADR treatment and NMT mice without 
ADR treatment. Each group consisted of 4 mice. These counting studies were done by 
an observer blind to the identity of the sections. 
Electron microscopy 
Tissues from ADR treated mice and control FVB mice were used. Mice 
were deeply anaesthetized with intraperitoneal injection ofketamine (100 mg/kg) and 
xylazine (32 mg/kg) then perfused through the heart with Tyrode solution, followed by a 
fixative of 1% paraformaldehyde and 3% glutaraldehyde in 0.1 m sodium phosphate 
buffer, pH 7.4 (PB). The kidneys were removed, weighed and decapsulated. They 
were then sliced longitudinally and the medulla from each slice was removed and cortical 
strips were cut into 1 mm3 tissue blocks. The blocks from each kidney were selected by 
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unbiased technical personnel and placed into cold fixative overnight and then the selected 
blocks were post-fixed in 2% osmium tetroxide, dehydrated with an ethanol series and 
embedded in Durcupan resin (Ted Pella Co.). Thick sections (250 nm) were cut and 
stained by toluidine blue for light microscope observation, ultra-thin sections (70-80 nm, 
silver-gray interference colour) were cut serially using a diamond knife. To avoid 
examining the same cells on multiple sections, every 10th section was collected on 
F ormvar-coated copper slot grids. Sections were then stained with 10% uranyl acetate 
in methanol for 30 min before examination with the transmission electron microscope. 
Statistical analysis 
Values are expressed as mean ± SE. Statistical analysis was performed 
using Microsoft-Excel and Sigma-Stat software. Significance of differences was 
determined by two-tail t test for single comparisons. Two way analysis of variance 
(ANOV A) with Holm-Sidak post-hoc test was used for multiple comparisons with 
genotype and ADR injection used as the two factors. P-values less than 0.05 were 
considered statistically significant. 
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RESULTS 
Changes of Urinary albumin excretion in FVB mouse after ADR treatment 
Initial dose- testing experiments between 9 and 13 mg/kg bodyweight ADR 
in wild-type FVB male mice suggested that a dose of 11 mg/kg adriamycin produced 
renal injury characterized by albuminuria and abnormal glomerular morphology. The 
lower dose of 9mg/kg bodyweight produced less nephropathy while a higher dose of 
13mg/kg bodyweight produced more than 50% death rate. Therefore we chose llmg/kg 
bodyweight as the right dose for establishing ADR-injected nephropathy in FVB mice. 
We checked 24-h urine excretion of albumin in FVB mice 5 days after ADR 
injection. This time point was chosen based on the results of Wang et al. [3], who 
reported that albuminuria increases 5 days after ADR injection. There was a 2-3- fold, 
significant elevation of urine albumin 5 days after ADR treatment (shown in Figure 1). 
This showed that ADR treatment injured kidneys ofFVB mice. 
Expression ofMT in Nmt transgenic and FVB control mice 
Oxidative stress has been reported to play an important role in Adriamycin 
(ADR)-induced nephropathy; and some antioxidant treatments have shown efficacy 
against ADR nephrotoxicity. Metallothionein is a low molecular weight, cysteine-rich, 
inducible protein, which is capable of scavenging many different types of ROS. Our lab 
developed a transgenic mouse line in FVB mice designated Nmt, which we have recently 
described [40]. In Nmt mice MT is over-expressed in podocytes using the 
podocyte-specific nephrin promoter (a more complete description of the Nmt trans gene is 
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contained in Zheng et al. [40]). The morphology ofNmt glomeruli appears normal and 
MT staining is clearly increased in Nmt glomeruli compared to FVB glomeruli, as shown 
in Figure 2. Also, elevated MT staining appears to be in the same cells that stain for 
WTl, illustrating that the increase in MT content is in podocytes. Using Nmt mice we 
demonstrated that over-expression ofMT in podocytes protects the diabetic mouse model 
OVE26 from albuminuria and reduces injury to podocytes and glomeruli [40]. 
In vitro protection of podocytes against ROS by MT overexpression 
We next determined ifMT over-expression protected transgenic podocytes 
from oxidative damage. Because podocytes are less than 20% of glomerular cells we 
needed a histological procedure that would allow us to identify both injury to cells and 
which cells were podocytes. To achieve this we examined the effect ofH202 on 
cultured glomeruli from transgenic and control mice. Cultured glomeruli were exposed 
to 880 f..lm H20 2 for 16 h. They were then stained for F-actin using Oregon Green 488 
phalloidin to examine cell injury. 
The morphology and fragmentation state ofF-actin filaments provides a 
marker for the health of many cultured cell-types [46,47], including podocytes [48]. 
The podocytes in the cell population were identified by staining for the podocyte marker 
WT 1. Both F -actin filaments and WT 1 were then examined by fluorescence 
mICroscopy. In podocytes, we observed that F-actin filaments were less sharply defined 
after H202 treatment (Figure 3). Also the filaments were localized less along the cell 
boundary and more towards the nucleus, which is similar to the findings of Huot et al. 
[46]. Figure 3 also shows that most Nmt podocytes were less susceptible to the 
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disruption by hydrogen peroxide than control podocytes. More Nmt podocytes retained 
well-organized longitudinal stress fibre structure. Semi-quantitive studies ofF-actin 
morphology after H20 2 treatment confirmed our observations that podocytes 
over-expressing MT were protected against H20 2-induced oxidative injury at the F-actin 
level. 
MT over-expression reduces ADR-induced albuminuria 
Based on our hypothesis that ADR nephrotoxicity would be attenuated by 
the MT -transgene, we measured 24-h urine albumin excretion following ADR injection 
in a group of non-transgenic FVB mice and a group of transgenic Nmt mice (Figure 4). 
In FVB mice, urinary albumin excretion (UAE) was elevated by the 5th day after ADR 
injection and tended to increase out to 21 days post-injection. Nmt mice also had 
elevated UAE by 5 days post-injection, but they tended towards recovery much more 
rapidly than FVB mice. UAE in Nmt mice was significantly lower than in the FVB 
mice at 5, 21 and 28 days after ADR injection. 
Podocyte staining and quantification 
In order to see ifMT over-expression helped maintain podocyte numbers, we 
counted the number of podocytes per glomerular cross-section in untreated and 
ADR-treated FVB and Nmt mice (Figure 5). Podocytes were identified by staining with 
an antibody against the podocyte marker WTl. Mice were sacrificed 5 days after ADR 
injection for podocyte counting. As shown in Figure 5, ADR treatment produced a 
significant (p <0.05) reduction in podocyte number in FVB mice of ~20%. However, 
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in Nmt mice ADR treatment did not significantly reduce podocyte number and the 
Nmt-ADR mice had significantly more podocytes per glomerulus than FVB-ADR mice. 
Podocytes ultra-structure by electron microscopy 
Podocytes ultra-structure was further examined using electronic microscopy. 
Compared to the distinct brush-like structure ofpodocytes foot processes shown in 
control mice (Figure 6A and D), fusion of podocytes foot processes developed in FVB 
mice at 5 days after ADR injection (Figure 6B and E). Nmt mice podocytes tended to 
retain relatively normal ultra-structures (Figure 6C and F), which means the NMT 
podoctes retained the relatively clearly defined brush like structures after ADR treatment. 
These results were representative of two Nmt and two FVB mice treated with ADR. 
Glomerular volume calculation 
Glomerular volume was estimated by light microscopy on H&E stained 
kidney sections according to the mathematical model of Weibel and Gomez [44,45]. FVB 
mice receiving ADR showed a trend towards reduced glomerular volume compared to 
control FVB mice (Figure 7), though the difference did not reach significance (p=O.117). 
In Nmt mice glomerular volume was not reduced at all by ADR injection and the 
glomerular volume ofNMT-ADR mice was significantly greater than that ofFVB-ADR 
mice (p<O.05) (Figure 7). 
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DISCUSSION 
In this study, we demonstrated that inbred FVB mice are susceptible to 
ADR-induced renal damage. This was evident as decreased podocyte number, reduced 
glomerular volume and significantly increased albuminuria. Furthermore, when we 
tested ADR toxicity in Nmt transgenic mice [40] that over-express MT specifically in 
podocytes, all parameters tested for ADR-induced nephropathy were significantly 
reduced. These findings show that podocytes are a direct target of ADR damage and 
that protection ofpodocytes by increasing expression ofMT reduces ADR nephropathy. 
The FVB strain of mice was selected for this study because it is the strain 
that Nmt transgenic mice was developed on. However, Zheng et aL [40] reported that 
among many strains tested, including FVB, only BALB/C mice were susceptible to ADR 
nephropathy. In contrast to their findings we observed that FVB mice were sensitive to 
ADR: ADR treatment increased albuminuria more than 2-fold, to~0.75 mg124 h. ADR 
also affected glomerular structure: Glomeruli tended to be smaller, as has been reported 
in ADR treated rats [49], and podocyte number per glomerular section was reduced. We 
believe that the reason our conclusion about ADR toxicity to FVB mice was different 
from that of Zheng et al. is that BALB/C mice are much more sensitive: ADR treatment 
increases albuminuria more than 20-times in BALB/C mice [50] but only two times in 
FVB mice. Also, ADR-induced morphological changes in FVB mice are less obvious 
and more difficult to measure than morphological changes in BALB/C mice. Both our 
morphological and albuminuria studies show that FVB mice are damaged by ADR, albeit 
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to a lesser extent than in BALB/C mice. The methods we used to detect ADR damage 
by albumin ELISA were more sensitive than the methods used by Zheng et al. and we 
believe that is why we observed ADR-induced injury to FVB mice when Zheng et al. did 
not. Zheng et al. identified the DOXNPH haplotype of BALB/C mice as critical to this 
strain's sensitivity to ADR. FVB mice do not carry this haplotype. It is possible that 
other strains of mice, in addition to FVB, that do not have the BALB/C haplotype also 
exhibit modest sensitivity to ADR. 
The renal cell-type(s) sensitive to ADR are uncertain. A number of renal 
cells are damaged by ADR treatment, including tubular epithelial cells [49] and 
glomerular cells[ 51]. Since different renal cell-types interact in vivo it is difficult to 
determine which cells are damaged directly and which are damaged indirectly. 
Glomerular podocytes are an important determinant of proteinuria. They are an 
essential component of the normal glomerular filtration barrier and injury to podocytes 
produces albuminuria. If ADR damages podocytes in vivo then this could cause the 
prominent proteinuria of ADR nephropathy. In vitro experiments with cultured 
podocytes indicate that they are sensitive to ADR toxicity [52]. To assess whether 
podocytes are a direct site of ADR injury in vivo, we protected them by targeted 
over-expression ofMT using the transgene Nmt, which uses the podocyte-specific 
nephrin promoter. Our results show that podocytes are a direct target of ADR toxicity, 
since the trans gene was not expressed in any other cell type. 
The mechanism oftoxicity by ADR has not been clearly established in the 
kidney. It is widely supposed that a major cytotoxic mechanism of ADR is to increase 
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ROS generation. MT is a potent antioxidant and our prior work demonstrated that 
transgenic over-expression ofMT in pancreatic beta cells and cardiomyocytes [30,41] 
increases scavenging of a broad range of ROS including peroxynitrite, superoxide and 
hydrogen peroxide. The in vitro experiments needed in this study to specifically 
examine podocyte damage showed that MT over-expression protected podocytes from 
oxidative injury. Therefore, MT protection against nephrotoxicity induced by ADR 
provides stronger evidence that ROS are a cause of ADR toxicity. However, because 
MT has actions in addition to scavenging ROS [53] and because we did not demonstrate 
changes in oxidative damage in podocytes, it is possible that MT reduced ADR toxicity 
by mechanisms other than reduced oxidative stress. 
Protective effects of MT over-expression were evident by morphological 
analysis. Five days after ADR treatment, Nmt glomeruli were larger and had more 
podocytes than FVB glomeruli. The ADR-induced decline in podocyte number was 
completely eliminated by the Nmt transgene. This action of MT may have been due to 
preventing ADR-induced podocyte death or it may have been due to reducing podocyte 
detachment. ADR also produced injury to podocytes' ultra-structure. Electronic 
microscopy studies showed that adriamycin caused podocyte foot process effacement in 
FVB mice and this damage appeared to be reduced by the NMT trans gene. The fact that 
MT over-expression in podocytes provided protection indicates that the injury was a 
direct action of ADR on the podocyte and that the damage was mediated through ROS 
toxicity. The mechanism behind the trend to reduced glomerular volume after ADR 
treatment is less clear. It is an abnormality that has also been observed in glomeruli of 
ADR-treated rats [49]. The reduction in podocyte number is not sufficient to explain 
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the reduction in total glomerular volume, because podocytes represent too small a 
fraction of the glomerulus. Since MT podocyte protection eliminated the reduction in 
volume, it is probable that the decrease in glomerular volume developed secondary to 
podocyte injury. Podocyte damage has been shown to have significant effects on other 
glomerular cells in vivo, such as mesanagial cells [54,55]. 
The clearest effect ofMT over-expression was that Nmt mice had less 
albuminuria after ADR injection. The initial rise in albuminuria at 5 days 
post-treatment was significantly less in Nmt mice and albuminuria rapidly declined in 
Nmt mice, whereas it continued to rise in FVB mice. This result is consistent with the 
protection observed for podocyte number and demonstrates that the cause of 
ADR-induced albuminuria in FVB mice is injury to the podocyte. 
In summary, our results show that ADR produce nephropathy in FVB mice 
and that MT protection of one glomerular cell type, the podocyte, is sufficient to protect 
all components from ADR nephrotoxicity. 
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Figure 1. Schematic diagram of Nephron. A) A nephron consists of glomerular 
capsule, proximal convoluted tubule, loop of Henle, distal convoluted tubule and 
collecting duct. B) Glomerulus is located within the Bowman's capsule. Blood is 
transported into the Bowman's capsule from the afferent arteriole, filtered through the 
glomerulus and passed out via the efferent arteriole. While not shown in this diagram, 
the glomerular capillaries are completely surrounded by podocytes that form a layer of 




_ 400 .. 
.l:. .... 




Untreated ADR Treated 
23 
Figure 2. ADR increases urine albumin (UAE) and total protein excretion in FVB 
mice. The graph shows 24-h urine albumin excretion from FVB mice before (untreated) 
and 5 days after ADR treatment (values are the means±SE of 15 mice, # indicates p 
<0.01). 
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Figure 3. Expression of MT in Nmt transgenic and FVB control mice. Light 
microscopy images at left show normal morphology in Nmt glomeruli. MT staining 
with DAB chromogen is indicated by brown colour in these panels. The fluorescent 
images show double-staining for MT (red) and WTl (green). In the merged image 
(yellow) indicates colocalization ofMT and WTl. Original light micrographs were 
















Figure 4. F-actin filaments are resistant to H 20 2 in Nmt podocytes. Green is 
Oregon green phalloidin staining for F -actin. Red is WTl staining for identification of 
podocyte nuclei. (A and D) Untreated Nmt and FVB podocytes. (B and C) Two 
examples of Nmt podocytes after 16 h of 880 ~m H20 2 exposure. (E and F) Two 
examples of FVB podocytes after H20 2 exposure. In many Nmt podocytes (B) the 
F -actin filaments retained their distinct structure and peripheral location after H20 2 
exposure. (G) Semi-quantitative analysis ofF-actin morphology after H20 2 exposure. 
F -actin fibres were rated by a blind observer whether they did or did not retain peripheral 
localization and whether or not the fibres were clearly defined (distinct). Scoring is of 
20 podocytes from three separate glomerular preparations per group. # indicates that 
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Figure 5. MT over-expression reduces ADR-induced albuminuria. Twenty-four 
hour urine albumin excretion plotted against time after ADR injection. Values are the 
mean±SE. # indicates p<0.05 for the difference between Nmt and FVB at that time 
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Figure 6. The NMT transgene preserves podocyte number. (A) FVB-control and 
(B) FVB-ADR show typical WTl staining of control and ADR-treated FVB glomeruli. 
Brown staining indicates podocyte nuclei. (C) Quantitative comparison ofpodocyte 
number among different groups. Kidney samples were taken 5 days after ADR injection. 
The asterisks indicate that podocyte number in ADR-treated FVB mice is lower than in 
either ADR-treated Nmt or non-treated FVB glomeruli (p<O.05 by two-way ANOV A, 
n~:4 mice per group). Vertical bars are the SEM. 
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Figure 7. The Nmt transgene improves podocyte ultrastructure of ADR-injected 
mice. (A and D) Normal structure ofpodocytes foot processes in a FVB mouse without 
ADR injection at low (5600 x) and high (9800x) magnification, respectively. (B) 4900x 
and (E) 8800x show effacement of podocytes foot processes in FVB mice 5 days after 
ADR injection. (C) 4900x and (F) 8800x show relatively normal foot processes in Nmt 
mice 5 days after ADR injection. (The scale bars on each panel represent I /lm.) ADR 
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Figure 8. Comparison of glomerular volume in ADR-treated FVB mice 
(FVB-ADR), ADR-treated Nmt mice (Nmt-ADR), control FVB mice (FVB-ControI) 
and control Nmt mice (Nmt-Control). The average volume of ADR treated FVB 
glomeruli was significantly less than the volume of ADR-treated Nmt glomeruli (# 
indicates p<0.05 by two way ANOVA). Kidney samples were fixed 5 days after ADR 
injection. Average glomerular volumes for each group were determined from 
measurement of 80 glomerular cross-sections measured in four different mice of that 
group. Values are the mean±SEM. 
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CHAPTER II 
GENE EXPRESSION DURING PROGRESSION OF DIABETIC 
NEPHROPATHY 
INTRODUCTION 
Diabetes and Diabetic Nephropathy (DN) 
Diabetes is a group of metabolic diseases marked by high blood glucose 
levels, resulting from defects in insulin production, insulin action or both. Diabetes is 
one of the leading causes of death in the United States and the world, it affects 7.8% of 
the population in the United States. About 1.6 million new cases of diabetes are 
diagnosed in people aged 20 years and older each year (fig 9A). Diabetes is a group of 
metabolic diseases marked by high blood glucose levels, resulting from defects in insulin 
production, insulin action or both. Diabetes can lead to serious complications such as 
heart attack (diabetic cardiomyopathy), kidney failure (diabetic nephropathy), blindness 
and nerve problems etc. 
Diabetes is the most common cause of end stage renal disease (ESRD) [56], 
accounting for about 44 percent of new cases of kidney failure (fig 9B). In 2007, 
48,871 people with diabetes began treatment for end-stage kidney disease in the United 
States. The basic mechanisms of Diabetic nephropathy (DN) are not well understood 
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and research is restricted by limitations in available diabetic models. Current animal 
models of DN do not exhibit many of the key clinical features of advanced human DN 
such as severely reduced GFR and extensive interstitial fibrosis [57]. However it is 
possible that the processes leading to advanced DN are already underway in these 
diabetic animals but they fail to reach renal failure due to the many years required to 
produce the damage seen in diabetic patients. 
Diabetic Nephropathy and Inflammation 
Diabetic nephropathy has become the major cause of end stage renal failure, 
however the mechanism underlying the progression of renal injury still remains unclear. 
There is increasing evidence that links inflammation with development ofDN. Recent 
data suggest that inflammatory markers such as interleukins and tumor necrosis factor 
(TNF)-alpha in the serum of patient with DN are increased [58,59]. Frederik et al has 
reported that inflammation marker (IL-6, fibrinogen, hs-CRP) were found as independent 
predictors of progression to DN in patients with diabetes and microalbuminuria [60]. 
In animal models ofDN, there are also studies that suggest that inflammation 
plays an important role in the development of renal injuries in diabetes. Chow and 
co-workers [61] indicated that the inflammation marker ICAM-l is a critical promoter of 
nephropathy in db/db mice, which is a mouse model of type 2 diabetes, by facilitating 
kidney macrophage recruitment. In OVE26 mice model of diabetes and DN, produced 
by our lab, an increase of inflammation markers such as interleukins and chemokines in 
renal gene expression is also observed in the diabetic kidneys. 
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These clinical findings and experimental studies support the role of 
inflammation in the development of DN. A further investigation of inflammatory 
pathways activated in DN may help discover important therapeutic targets for diagnosis 
and treatments for DN. 
Vitamin D and renal inflammation in Chronic Kidney Disease 
Vitamin D has now been recognized to possess immunomodulatory 
properties that are mediated by vitamin D receptor (VDR), which is found to be 
expressed on several immune cells, especially antigen-presenting cells such as 
macrophages, dendritic cells and both CD4+ and CD8+ T-cells [62,63]. Active vitamin 
D has also been reported to down-regulate the production of several inflammatory 
cytokines [64], the regulation is mediated through interference with nuclear transcription 
factor such as NF-kB [65]. 
Renal inflammation, characterized by the inflammatory cells infiltrating into 
glomerulus and tubulointerstitium, plays a role in the evolution of chronic kidney 
diseases (CKD) [66]. Several clinical studies discovered the declining renal function is 
closely related to the extent of inflammation in CKD patients [67]. Vitamin D 
deficiency is observed as an early pathological feature ofCKD [68]. In nephropathy 
patients, there is a significant correlation between expression of CYP27B 1, the rating 
limiting enzyme for formation of active vitamin D and renal inflammation [69]. 
Conversely, in CKD patients, active vitamin D treatment reduced proteinuria and 
all-cause mortality [70,71,72]. It has been proposed that the potential mechanism is 
related to the anti-inflammatory effect of vitamin D in CKD. 
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Several lines of evidences support the anti-inflammatory role of vitamin Din 
CKD. In mouse models of type I diabetes (TID) and type 2 diabetes (T2D), 
supplementary vitamin D reduces renal inflammation and DN [73]. In mouse model of 
obstructive nephropathy, active vitamin D analogue inhibited renal inflammatory 
infiltration and expressions of pro inflammatory cytokines [68]. Zehnder et al found in 
patients with kidney disease, there's a inverse correlation between renal inflammation 
and serum active vitamin D level [69]. The underlying mechanisms of vitamin D's 
anti-inflammatory activity is still needing further investigation, it has been suggested that 
the mechanism is through VDR mediated sequestration ofNF-kB signaling [68]. 
OVE26 Diabetic Mouse Model 
OVE26 mice were produced by introduction of a calmodulin transgene 
regulated by rat insulin promoter into FVBINJ mice, which caused beta cell specific 
damage[74]. This beta cell impairment in OVE26 mice causes the mice to become 
diabetic within a week of birth and eventually develop severe hyperglycemia. The mice 
can survive over a year without insulin treatment because of sufficient residual insulin 
secretion. According to the criteria established by the NIDDK, our OVE26 mice show 
great potential to be a good model for type I diabetes. Compared to non-diabetic 
controls, OVE26 mice also exhibit albuminuria by 2 months of age and progress to 
significant albuminuria as the age goes up [16]. Severe interstitial fibrosis, mesangial 
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expansion and glomerular basement membrane (GBM) thickness are also observed in the 
OVE26 model. GFR also shows a small reduction at 9 months age. For all of the 
reasons above, OVE26 mice seem to be a suitable model for us to investigate gene 
expression changes during the development ofDN. 
Our OVE26 mice survive at least one year so it provides an ideal model for 
analyzing the gene expression change during the chronic progression of the disease. 
Analyzing diabetic kidneys at different time points will be helpful to understand how the 
disease progresses, which changes are primary and what time points are most important. 
Currently we have run the microarray gene expression assay on whole kidney from 2 
month old, 4 month old and 8 month old diabetic mice and FVB control mice. 
Microarray and DN 
Microarray technology evolved from Southern blotting, where fragmented 
DNA is attached to a substrate and then probed with a known gene or fragment. It is 
increasingly used by biologists to measure changes of gene expression level, to detect 
single nucleotide polymorphisms (SNPs), to genotype or resequence mutant genomes. 
The process of measuring gene expression via cDNAlcRNA is called expression analysis 
or expression profiling. 
Chronic diseases like diabetes are likely to affect the gene expression 
profiles. Surrogate end points, such as changes in renal gene expression are needed to 
evaluate the progression of disease in animals. Gene expression studies can be used to 
identify individual protein targets or they can be used to recognize major signaling 
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pathways activated in diabetic tissues. A number of genes and pathways have been 
identified in advanced DN of human kidney samples and also in kidneys from the Type 2 
diabetic db/db mouse model [75,76]. Studies on gene expressions will be useful for 
investigating the molecular pathways involved in development ofDN. New gene chips 
available from Affymetrix allow for analysis of all the genes produced by DN mouse 
model. 
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METHODS AND MATERIALS 
Animals 
Our lab developed OVE26 transgenic mice on the FVB background by using 
a transgene to over-express calmodulin in pancreatic beta cells [74]. Normal female 
FVB mice and diabetic female OVE26 mice were sacrificed at 2, 4 and 8 months of age. 
Kidneys, serum and urine samples were harvested. Mice were housed in HEAP-filtered 
ventilated cages in the University of Louisville Research Resources Center under barrier 
conditions, with free access to water and Purina Mills #5001 Laboratory Rodent chow. 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee, which is certified by the American Association of Accreditation of 
Laboratory Animal Care. 
Chemicals 
RNA extracting reagent Trizol was purchased from Invitrogen Life 
Technologies (Carlsbad, CA); High-Capacity cDNA Archive Kit was purchased from 
Applied Biosystems (Foster City, CA); Taqman pre-made probes and reagents were 
purchased from Applied Biosystems (Foster City, CA); rabbit polyclonal anti-mouse 
CD44 was purchased from Abcam Inc (Cambridge, MA); biotinylated secondary 
antibodies and Vectastain ABC kit were purchased from Vector Labs Inc (Burlingame, 
CA); rabbit anti-mouse albumin antibody was purchased from Bethyl Laboratories 
(Montgomery, TX); FITC-conjugated goat anti-mouse C3 was purchased from MP 
Biomedicals (Cleveland, OH), rat monoclonal anti-mouse F4/80 was purchased from Cell 
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Sciences (Canton, MA), goat anti-mouse VCAMI was purchased from R&D Systems 
(Minneapolis, MN); 1 ,25-dihydroxyvitamin D ELISA kit was purchased from 
Immunodiagnostic System (Scottsdale, AZ). 
RNA isolation and Microarray procedures 
Total RNA was prepared from flash frozen left kidney, excised from 
ketamine/xylazine anesthetized mice. The kidney was pulverized under liquid nitrogen 
and RNA extracted using Trizol reagent (Invitrogen, CA) following the manufacturer's 
protocol. The quantity of cellular RNA was determined by UV absorbance, and 
integrity monitored with an Agilent BioAnalyzer 2100 using nano- or pico-chips. 
Preparation of cDNA was carried out using the one-cycle cDNA synthesis kit with 
0Iigo-dT-T7 promoter primers (Affymetrix, Inc.). The cDNA served as template for T7 
RNA polymerase transcription in the presence of biotin-labeled CTP and UTP. The 
cRNA was fragmented to a size range of 50-200 nucleotides. Probes were hybridized to 
Affymetrix MG-430 2.0 GeneChips. 
Signal intensity data comparisons between control and diabetic samples at 
each age were compared using SAM 3.0 [77] and a minimal false discovery rate of 
P<0.05. For comparison of multiple factors (age and diabetes) a two-way ANOVA of 
signal intensity was done with Partek Genomic Suite v5.2 (St.Louis, MO). Lists of 
significantly altered genes and fold change data were imported into Ingenuity Pathway 
Analysis (Redwood City, CA) for biological interpretation. 
RT-PCR 
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Single strand cDNA was synthesized from the extracted RNA using 
High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) following the 
manufacturer's instructions. The cDNA was then amplified on a thermo cycler (7300 
Real time PCR system, Applied Biosystem) using commercially available Taqman 
reagents (Assay on demand, Applied Biosystem) for C3, Fasn and Hmgcr. 18S 
ribosomal RNA was used for results normalization. The amplification profile used 40 
cycles of denaturation at 95°C for 15 sec, primer annealing/extension at 60°C for 1 min. 
The mRNA expression levels of the selected genes were normalized to 18s ribosomal 
RNA in each sample. Relative expression ratio was calculated according to the 2-MCT 
method. Duplicate runs were performed on each sample. 
Immunohistochemistry 
Kidneys removed from anesthetized mice were immediately cut in half and 
fixed in 10% formaldehyde in 0.1 M phosphate buffered saline (PB S, pH 7.2), and 
transferred to 70% ethanol after 24 hours in fixative. The kidney was then embedded in 
paraffin and sectioned at 5 )lm. Following deparaffinization and hydration, the sections 
were subjected to antigen retrieval using 10mM citrate buffer (pH 6.0) in a decloaking 
chamber (Biocare Medical, Concord, CA) at 125"C for 5 minutes, then washed in PBS. 
For labeling ofCD44, endogenous peroxidases were first blocked with 3% hydrogen 
peroxide in water, then nonspecific binding was blocked with normal serum for 20 
minutes at room temperature. The sections were then incubated 1 hour at RT with 
rabbit polyclonal anti-mouse CD44 (1: 100, Abcam, Inc, MA), washed and then incubated 
with the biotinylated secondary antibody (Vectastain ABC kit, Vector Labs Inc, CA). 
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Peroxidase activity was identified by reaction with 3,3' -diaminobenzidine (Vector Labs 
Inc, CA). 
For immunofluorescence labeling, sections were first blocked with normal 
serum, then incubated overnight at 4°C with the following primary antibodies: rabbit 
anti-mouse albumin (1 :500, Bethyl Laboratories, TX), FITC-conjugated goat anti-mouse 
C3 (1: 1 00, MP Biomedicals, OR), rat monoclonal anti-mouse F4/80 (1 :40, Cell Sciences, 
MA), rabbit polyclonal anti-mouse CD44 (1 :100, Abcam, Inc, MA) or goat anti-mouse 
VCAMI (1 :10, R&D Systems, MN). After washing in PBS, the sections (except for 
those with FITC-Iabeled C3) were incubated with the following secondary antibodies 
(1: 100) for 1 hour at RT: anti-rabbit FITC or Cy3, anti-rat Cy3, anti-rabbit AMCA or 
anti-goat Cy3. Images were captured using a Nikon DS-Fil camera system with a 
Nikon E600 microscope. 
Generation of complement C3 RNA probe and in situ hybridization 
A probe designated pC3-l-4l4 was prepared from a plasmid containing a 
5088bp cDNA insert of complement C3 in the multiple cloning site of the vector 
pCMV-SPORT6 (American Type Culture Collection, VA). The probe plasmid 
pC3-l-414 was constructed by cutting the original C3 plasmid with RindIII (RindIII cuts 
the C3 cDNA at position 414, 5056 and in the multiple cloning site of the 
pCMV-SPORT6 vector at position 743). The cut plasmid was religated leaving the first 
414 bp of the C3 eDNA in the plasmid. Antisense digoxigenin-Iabeled C3 transcripts 
were produced by linearizing pC3-1-414 with SalI and transcribing with T7 RNA 
polymerase. Sense transcripts were produced by linearizing with HindIII and 
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transcribing with SP6 RNA polymerase. Labeling was performed according to the 
manufacturer's instruction (Roche) and hybridization was done essentially as described 
[78]. After frozen sections were dried at 50°C for 15min, they were fixed in 4% 
paraformaldehyde, then treated with 2ug/ml proteinase Kat RT for 5 min. Following a 
1 hour prehybridization step, sections were then hybridized overnight at 65°C with 100ui 
hybridization buffer (5xSSC, 5xDenharts, 250ug/ml bakers yeast RNA, 500ug/ml herring 
sperm DNA, 50% formamide) containing 100-200ng/ml of digoxigenin-Iabeled probes. 
After washing three times in pre-warmed 0.2xSSC at 6YC and once with 0.2xSSC at RT, 
the sections were blocked in buffer (O.1M Tris, 0.15M NaCI, pH 7.5) containing 10% 
sheep serum for 1 hour at RT, then incubated with an alkaline phosphatase-conjugated 
anti-digoxigenin Ab (Roche) diluted 1 :5000 in the blocking buffer at 4°C overnight. 
After subsequent washes, sections were developed with NBT/5-bromo-4-chloro-3-indolyl 
phosphate (Roche), dried in air, mounted and examined under light microscopy. 
Measurements from urine and serum 
For determination of urinary albumin excretion, mice were placed 
individually in metabolic cages with free access to chow and 10% liquid diet (Glucerna, 
Abbot Laboratories). Urine was collected for 24 h and albuminuria was measured using 
a mouse albumin ELISA kit (Bethyl Laboratories). The dilution of sample urine was 
adjusted to place the albumin concentrations within the linear range of the ELISA assay. 
Blood was collected by cardiac puncture. Serum 1,25-dihydroxyvitamin D levels were 
measured by the commercial ELISA kit (Immunodiagnostic System, UK). Serum 
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calcium levels were measured using calcein as a calcium indicator relative to calcium 
standards on a Hitachi F-2500 fluorescence spectrometer. 
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RESULTS 
Progression of DN and Altered Gene Expression in OVE26 Diabetic Mice 
In OVE26 mice diabetes begins within a few days of birth indicated by 
high blood glucose. Blood glucose climbs up to 2 months of age and then drops 
gradually thereafter (82S±37, 760±36, 71O±41 at 2,4 and 8 months of age, respectively 
P>O.OS versus FVB). Figure lOA shows that albuminuria in the female OVE26 mice 
used in this study became much worse with age, averaging 800 ug per day at 2 months, 
climbing to 10,000 ug by 4 months and averaging over 100,000 ug at 8 months. At all 
ages non-diabetic mice averaged less than 2S0ug per day. 
Kidney RNA was made from OVE26 mice and control FVB mice at 2, 4 and 
8 months of age (n~6 per group). Gene expression profiles were determined on 
Affymetrix MG-430 2.0 arrays and analyzed using SAM 3.0 [78] with a minimal false 
discovery rate ofP<O.OS. The number of genes altered in expression by diabetes 
increased (Figure lOB) from 348 genes at 2 months to 6172 genes at 8 months. 
To identify genes and pathways that changed as a function of the duration of 
diabetes we ran a two-way ANOV A (Partek Genomic Suite) using age and diabetes as 
factors. This analysis combined the control and diabetic data at all ages and found 380 
genes significantly altered by both age and diabetes. This gene set was then uploaded to 
the online database Ingenuity. Figure 11 shows the 10 most significant biological 
functions identified by Ingenuity. Three of the top five biological functions and/or 
diseases are directly related to inflammation. The number of inflammatory response 
genes (identified by Ingenuity data base program) up-regulated by diabetes (Figure 12) 
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increased with age more than the overall change in gene expression. Some of the 
specific inflammatory response pathways upregulated are shown in Table 1. Of all 
pathways for all functions Ingenuity identified leucocyte extravasation and NfkappaB as 
the two most significant pathways at 8 months of age. Specific inflammatory genes 
elevated over 1.5 fold at 8 month diabetic kidney are shown in Table 2, arranged by 
category. 
Inflammatory Genes Expressed in Diabetic Mouse Kidney 
Complement component 3 (C3): 
e3 was the only inflammatory response gene elevated at 2 months of age. 
e3 was increased two-fold (Figure 13A) at 2 months and this progressed to almost 9-fold 
at 8 months. Within the diabetic 8 month group there was positive correlation of 0.82 
(P<0.05) between albuminuria and e3 signal intensity (P<0.05). Quantitative RT-peR 
validated the e3 array results (Figure 13B and C). e3 immunohistochemistry staining 
was increased, primarily in tubules with excessive albumin accumulation (Figure 13D-F). 
No e3 or albumin staining was seen in FVB tubules (Figure 13G-I). Since tubular e3 
can come from leakage through the glomerulus or from expression within the tubule, we 
assessed e3 gene expression by in situ hybridization (Figure 13J-L). Only minor 
staining was present in 8 month FVB mice (Figure 13J) but hybridization to 8 month 
diabetic kidney labeled most tubules and strongly labeled some tubules (Figure 13L). 
The sense probe did not hybridize to any tissue (not shown). To determine ifthere was 
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a relation between albumin accumulation and C3 mRNA, serial sections were stained for 
albumin by immunofluorescence and for C3 mRNA. As shown in Figures 13L and 
13M the tubule with the highest level of C3 hybridization had the strongest accumulation 
of albumin. 
VCAMl: 
VCAMI promotes the adhesion of infiltrating cells. VCAMI mRNA was 
elevated more than 4 fold at 8 months of age but not at earlier ages (Figure 14A). 
Pearson correlation analysis ofVCAMI signal intensity versus albumin excretion (Figure 
14B) demonstrated a correlation of 0.93 (P<O.OOl) within the group of 8 month diabetic 
mIce. Antibody staining (Figure 14C,D) showed that VCAMI expression was elevated 
in a fraction of the diabetic tubule population, but unlike C3 staining, the positive stained 
VCAMI tubules did not stain for albumin (Figure 14E,F). Since VCAMI is a 
membrane bound protein it is unlikely that glomerular leakage ofVCAMI contributed to 
tubular staining, unlike serum proteins such as albumin and C3. 
CD44: 
CD44 is an inflammatory response, membrane bound protein with multiple 
functions including regulation of VCAM 1 expression [79] and promotion of macrophage 
infiltration. Compared to FVB control, the average microarray signal was increased 8.9 
fold in OVE26 kidney at 8 months of age (Figure 15A). Pearson correlation analysis on 
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expression of CD44 versus albumin excretion (Figure 15B) indicated a highly significant 
correlation (coefficient=O.982, P<O.0005). Immunohistochemistry (Figure 15C-F) 
confirmed the microarray results and showed that increased staining was in tubular 
epithelial cells of OVE26 mice, as was seen for C3 and VCAM 1. However, CD44 
staining was more common and many CD44 stained tubules were partially or grossly 
dilated (Figure 15E) Age-matched controls had weak staining (Figure 15C). Also, 
diabetic kidneys with lower urinary albumin (Figure 15D) had weaker staining than those 
with higher urinary albumin (Figure 15E,F). And, as was observed for C3 staining, 
strong CD44 staining was associated with albumin accumulation (Figure 15G,H). 
Macrophage infiltration: 
The up-regulated genes described so far are implicated in inflammatory cell 
infiltration such as macrophages. Therefore we examined microarray results for the 
macrophage marker CD68 (Figure 16A). Elevated diabetic expression ofCD68 was 
evident only at 8 months of age. Also there was a clear correlation (Figure 16B) 
between albuminuria and expression of CD68 in 8 month diabetic mice (correlation 
coefficient=O.98, P<O.0005). To assess whether there was a physical association 
between macrophage and albumin accumulation we double stained kidneys with F4/80 
macrophage antibody and antibody to mouse albumin (Figure 16C, D). Macrophages 
were found in diabetic kidney but rarely in control kidney. In this example the 
macrophages were in close proximity to tubules that had accumulated albumin, though 
this was not always the case. 
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Relative localization of inflammatory gene products: 
Individual staining for C3, CD44 and VCAMI gave the impression that the 
prevalence of tubules staining for each protein was different. To test this directly, we 
triple stained OVE26 sections for each of these markers (Figure 17). Consistent with 
separate staining results (Figure 17) the most prevalent staining was for CD44 and in 
some cases the same tubules stained for C3. VCAM1 stained tubules did not stain for 
CD44 or C3 and VCAMI was not induced in dilated tubules (Figures 14 and 17). 
Based on thickness, brush border and megalin staining (not shown), most stained tubules 
were proximal tubules. 
Expression of CYP27B 1 and Vitamin D Level in OVE26 Diabetic Kidney 
Renal inflammation induces CYP27B1 [69], the rate limiting enzyme 
catalyzing synthesis of active vitamin D (1 ,25-dihydroxy vitamin D). In 2 and 4 month 
old OVE26 mice CYP27B 1 mRNA level was increased 3 to 4 fold above control mice 
and this rose to 9 fold at 8 months age (Figure 18A). Unlike other inflammatory 
proteins, its mRNA expression did not correlate with albuminuria (data not shown). 
Immunohistochemistry confirmed the diabetes induced elevation of CYP27B 1 expression 
(Figures 18C,D). As reported [80] CYP27B1 protein was present in most kidney cells. 
Given both altered mRNA and protein expression of this enzyme in diabetic mice, we 
53 
measured serum level of its hydroxylation product 1 ,25-dihydroxy vitamin D. Serum 
1 ,25-dihydroxy vitamin D was increased 2.4 fold in diabetic mice (Figure ISB). Since 
vitamin D is a regulator of in vivo calcium homeostasis, we also measured serum Ca2+ 
levels and found that serum Ca2+ levels were reduced in diabetic mice (S.6±O.3 mg/dl for 
OVE26 and 9.S ±O.1 mg/dl for FVB, P<O.OI, n=5) (Figure ISE). A correction analysis 
were performed to adjust the effect of reduced serum albumin level on total serum 
calcium measurement in OVE26 mice and the adjusted results showed similar reduction 
of serum calcium levels in diabetic mice. (data not shown) 
Expression of Fat Metabolism Genes in OVE26 Diabetic Kidneys 
We found one prior paper that examined changes in gene expression in 
OVE26 kidney [SI]. That study used syber green rtPCR to identify 2 to 3 fold changes 
in expression of 14 genes of fat metabolism or their transcriptional regulatory genes 
SREBPs I and 2 and PP ARs a and ( They proposed that increased OVE26 renal fatty 
acid and cholesterol content were due to combined reductions in transcription of mRNA 
for fatty acid oxidation genes and cholesterol efflux genes plus increased transcription of 
mRNA of fatty acid and cholesterol synthesis genes. In this study, using gene array, we 
found none of the changes previously reported for these 14 genes (Table 3). Five genes 
for fatty acid synthesis or transcriptional regulators were reported to be up-regulated in 
the previous study, but we did not find these genes up-regulated. In fact three were 
down-regulated. Two genes of fatty acid synthesis and two genes of cholesterol efflux 
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were previously reported to be increased but all were unchanged in the present study. 
Two genes of cholesterol synthesis were reported to be up-regulated, but we found them 
to be essentially unchanged. These results at 4 months of age were consistent with our 
results at 2 months and 8 months of age (data not shown). 
As shown in figure 19, the reduction in expression found for F ASN was 
confirmed by Taqman RT peR (fold change 0.43+0.07 ,respectively, P<0.05 by t-test). 
The most notable aspect of the current results is that the 4 genes that were significantly 
down-regulated are all induced by nuclear receptor SREBFl [82,83]. (Figure 20) 
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DISCUSSION 
This study provides the initial microarray analysis of the OVE26 kidney and 
thus the first study of gene expression changes of whole kidney during the development 
from mild to very severe diabetic albuminuria. Future studies will assess changes in 
gene expression of isolated glomeruli and podocytes. In OVE26 mice the daily albumin 
excretion progressed from lmg at 2 months to profound albuminuria of almost 100mg at 
8 months. The progression of albuminuria was paralleled by a significant alteration in 
gene expression of over 6000 kidney genes. Ingenuity pathway analysis indicated that 
the inflammatory response pathway was the most overrepresented biological pathway, 
and expression in this pathway increased almost exponentially with the progression of 
albuminuria. Inflammatory genes of the complement pathway that have not been shown 
to be up-regulated in other animal models of diabetes were greatly elevated in OVE26 
kidneys. 
Albuminuria, NF -kappa B and The Inflammatory Gene Response 
Human renal gene expression profiles have also linked inflammatory 
pathways to DN [76,84]. In animal models ofDN, some papers reported up-regulation 
of several inflammatory genes [85] but others did not [86]. We proposed that the 
stimulus for the increase in 300 inflammatory response genes in older OVE26 kidneys 
was due to their extreme albuminuria, which by 8 months was more than 500 fold higher 
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than in non-diabetic mice. This is in contrast to a 34-fold or lower increase in 
albuminuria in other diabetic models [5,87,88]. In fact the OVE26 inflammatory 
response at 4 months of age, when albuminuria was induced only 30 fold, was not 
especially prominent and included less than 25 genes. The association between severe 
albuminuria and gene expression does not prove that protein leakage caused the observed 
changes in inflammatory gene expression. However the role of albumin leakage is 
supported by the fact that there was a very strong correlation to albuminuria between 
individual diabetic mice of the same age and by the co-localization of albumin staining 
and staining for several inflammatory genes. 
The pro-inflammatory role of proteinuria is consistent with numerous in vitro 
studies where protein exposure of tubule epithelial cells activated Nf-kappa Band 
induced inflammation (reviewed in [89]). Ingenuity pathway analysis (Table 1) showed 
that the NF-kappa B pathway was significantly upregulated in 8 month diabetic kidneys. 
Schmid et al [76] proposed that the NF-kappa B promoter module NFKB_IRFF _01 was a 
marker of advanced human DN since they found induction of 8 of 9 genes controlled by 
this promoter module in progressive human DN samples. Of the 8 genes identified by 
Schmid et aI, we found 6 (VCAM1, CXCLlO, CCL5, HLA-B, EDNI and B2M) were 
upregulated in our oldest age diabetic group but none in our younger age diabetic groups. 
Analagous to the activation of the NFKB _ IRFF _ ° 1 module in advanced human DN, our 
results suggest that progressive DN develops between 4 and 8 months of age in OVE26 
mIce. 
Complement Component C3 
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C3 mRNA was the only inflammatory response gene up-regulated in 2 
month old diabetic mice and the expression level increased markedly with age and 
albuminuria. C3 over-expression was confirmed by RT-PCR and in situ hybridization. 
In vitro studies have demonstrated that exposure of cultured tubular cells to serum 
proteins increases C3 expression [90]. Urinary C3 induction has been reported in 
human diabetic nephropathies [91] but not to our knowledge in tubules of any other 
diabetic animal models. Again, this may be because other diabetic models have less 
proteinuria than OVE26 mice. In situ results showed that C3 mRNA was increased in 
most OVE26 tubules and serial section analysis showed that the strongest C3 reaction 
co-localized with the most intense albumin immunostaining, providing further evidence 
that C3 induction in diabetic mouse tubular cells is secondary to excessive albumin 
leakage into the proximal tubules. 
C3 can produce direct tissue damage and promote inflammation. Renal 
accumulation of C3 has been shown to be a major component of the pathology of several 
non-diabetic nephropathies [92,93] and inhibition ofC3 has been shown to be highly 
beneficial to mouse models of nephropathy [93,94] though this has not been tested in 
diabetic models. Chronic activation of C3 promotes further inflammation and activation 
of C3 expression in tubules of young OVE26 mice may have contributed to the further 
stimulation of additional inflammatory response genes. Since OVE26 mice are the first 
diabetic model to demonstrate C3 accumulation in the kidney, they provide the first 
opportunity to examine the importance of C3 in the progression of DN. It is notable that 
the background strain for OVE26 mice, FVB is deficient in C5, which prevents formation 
58 
of the membrane attack complex. Complement mediated damage in FVB mice is 
largely limited to cleavage products ofC3. Crossbreeding to add a functional C5 gene 
should result in more severe DN more closely mimicking human DN. 
Adhesion molecules and macrophage infiltration 
Two inflammatory response genes that were up-regulated more than 4-fold at 
8 months of age but not at earlier ages were VCAMI and CD44. Among other activities, 
both proteins increase adhesion of infiltrating cells. In normal control tissue 
VCAM-l was present on some (but not all) parietal epithelial cells lining Bowman's 
capsule, additional presence ofVCAM-l on proximal tubular cells was observed in 
clinical biopsy specimens from patients with diabetic nephropathy. Tubule VCAMI 
expression is induced by the NF-kappa B transcriptional pathway [76,95]. In diabetic 
patients, induction ofVCAMI expression may serve as a marker for progressive DN with 
2.5 fold higher expression in advanced DN samples compared to samples from patients 
with early DN or minimal change disease [76]. We did not find reports ofVCAMl 
induction in other animal models ofDN. CD44 is induced in kidneys injured by 
ischemia [96] or autoimmunity [97] and CD44 contributes to renal neutrophil and 
macrophage infiltration [98]. Induction of CD44 has not been reported in diabetic 
kidneys and CD44 is not induced in proximal tubule cell lines by high glucose [99]. 
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Expression of both VCAM 1 and CD44 genes displayed correlation 
coefficients greater than 0.9 versus the level of albuminuria. As shown by 
immunohistochemistry both proteins localized to tubule epithelial cells within what 
appeared to be proximal tubules, as indicated by the thickness of the tubule wall and the 
presence of a brush border and megalin. This localization is consistent with prior 
reports for CD44 [97] and VCAMI [95]. However, despite the fact that both CD44 and 
VCAMI were induced in proximal tubule cells at the same age, 8 months, they were 
induced in different tubules. Several characteristics differentiated CD44 and VCAM I 
positive tubules. CD44 cells were much more abundant than VCAMI cells. CD44 
stained tubules were often positive for albumin and C3 staining and CD44 positive 
tubules were often grossly dilated. In contrast VCAMI positive tubules did not stain for 
albumin or C3 and they never exhibited grossly dilated lumen. We recently reported 
[100] that tubules that accumulate albumin have a damaged brush border and abnormal 
epithelial cell protrusions extending into the tubular lumen, indicating that albumin 
accumulation produces significant proximal tubule cell injury. The greater damage, 
evident in CD44 positive cells as suggested by dilation and albumin accumulation, 
suggests that CD44 and VCAMI expression are associated with different stages of tubule 
pathology. 
Macrophage infiltration is commonly observed in diabetic and non-diabetic 
renal disease and is widely considered to contribute to chronic renal damage. CD68 is a 
macrophage protein used as a marker for macrophage infiltration. In OVE26 kidneys, 
CD68 expression followed the common inflammatory response pattern of not increasing 
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significantly until 8 months of age, at which time it was elevated 5.6-fold. A search of 
the Ingenuity database for the term macrophage returned six genes, of which 5 were 
significantly increased in the diabetic 8 month dataset. It is likely that the late increase 
in the renal leukocyte extravasation pathway genes (Table 2) such as CD44 and VCAMI 
paralleled the time course of macrophage infiltration and CD68 gene expression. 
CYP27B 1 and serum vitamin D levels 
Vitamin D is now recognized as a modulator of the immune system [101]. 
There are also findings that low vitamin D levels are related to increased inflammation in 
human renal diseases [69]. In mouse models of Type 1 and 2 diabetes, supplementary 
vitamin D reduces diabetic nephropathy and renal inflammation [73]. In nephropathy 
patients [69] there is a significant correlation between expression of CYP27B I, the rate 
limiting enzyme for formation of active vitamin D and renal inflammation. Elevated 
serum vitamin D and CYP27Bl expression have been reported in the dbdb Type 2 model 
ofDN [73]. 
In OVE26 mice CYP27B 1 was the third most upregulated gene at 2 months 
of age. At this age OVE26 mice have already attained extremely high blood glucose 
levels [16] but they do not exhibit renal inflammation or significant albuminuria. This 
suggests that severe hyperglycemia is sufficient to induce the CYP27B 1 gene. 
Alternatively, low serum calcium in OVE26 mice, is also known to stimulate CYP27BI 
expression [102]. The fact that CYP27Bl expression increased another 3-fold at 8 
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months of age, when albuminuria and inflammation increased indicates that these factors 
produce further induction of gene expression. Presumably as a result of increased 
expression of CYP27B 1 protein, serum levels of vitamin D were two fold elevated in 8 
month old OVE26 mice. While this may have partially ameliorated renal and systemic 
inflammation it was clearly not sufficient to prevent the inflammatory response of the 
OVE26 kidney. 
Fat metabolism gene expression 
This analysis of diabetes effects on fat metabolism genes revealed 
significant reductions in expression of 4 genes of fatty acid or cholesterol synthesis, 
SREBF 1, F ASN ACACA and HMGCR. SREBF I is a transcription factor that induces 
its own expression as well as expression of many enzymes of fat synthesis including 
HMGCR, FASN and ACACA. Further analysis showed many other SREBFl regulated 
genes were reduced at 4 and/or 8 months of age (Figure 20) and UCP2 and SLC2A2 
genes that are repressed by SREBF 1 were significantly increased. Thus the reduction in 
SREBF 1 plays a large role in these changes of gene expression. The SREBF 1 gene is 
responsive to insulin, therefore the virtual absence of insulin in OVE26 mice can explain 
the decline in SREBF 1 expression. 
Procotor et al [81] proposed that diabetes induces coordinate changes in 
mRNA expression for genes integral to fat metabolism resulting in increased fatty acid 
and cholesterol content in diabetic kidney. This then accelerates nephropathy. We 
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have also observed elevated renal cholesterol content in OVE26 kidney [103] however in 
the current study we did not confirm the changes reported for expression of 14 genes of 
fatty metabolism in OVE26 kidneys. In fact where expression changes were observed 
they were in the opposite direction to what was reported by Proctor et al. Our findings 
do not support the previous hypothesis that diabetes induced changes in renal nuclear 
transcription factors for genes of fatty acid metabolism promotes DN. The reliability of 
our results are supported by the fact that they were consistent at multiple ages and they 
were confirmed for the F ASN gene by probe based rtPCR. They are also supported by 
comparison of our data to a very recent publication [104] that found elevations in the 
mRNA levels for 3 genes in OVE26 kidney cortex of 7 month old mice by rtPCR. That 
studied found increases for serpine1, TGF~l and TGF~ induced mRNAs of 4.3, l.9 and 
1.4 fold, respectively, while we found by gene array analysis similar increases of 2.8, 1.7 
and 1.8 fold for the same genes at 8 months of age. 
Summary 
Microarray expression analysis shows that OVE26 mice develop features of 
advanced DN between 4 and 8 months of age. Overall inflammatory gene expression 
increases dramatically in association with increasing albuminuria and activation of 
NF-kappa B dependent pathways. As shown in Figure 21, OVE26 mice display 
elevated expression of C3 at an early stage of diabetes, which is possibly induced by the 
moderate protein leakage. When OVE26 mice aged and entered late stage of diabetes, 
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they exhibited excessive protein leakage. At this stage, C3 expression elevation may be 
reinforced by increased pro-inflammatory cytokines expression (indicated in table 2) and 
induced by accumulated albumin in tubules. Increased urinary albumin level was 
associated with elevated expression of adhesion molecules, VCAM I and CD44. The 
Nf-kB inflammatory pathway was up-regulated in late stage diabetes and positively 
regulated VCAM-I expression [76,95]. The expression of these genes (C3, VCAM-I, 
CD44) appears to be regulated differentially in different OVE26 tubules depending on the 
level of pathology in each nephron. These proteins have been shown to playa role in 
kidney injury in non-diabetic animal models of nephropathy but that have not been 
shown to be elevated in other models of diabetic kidney disease. Figure 21 provides a 
visual scheme for this proposed pathway for progression of diabetic nephropathy. 
Based on our immunohistochemistry results, increased macrophage infiltration was also 
related to tubular albumin leakage. Expression of CYP27B 1, the regulator of active 
vitamin D synthesis was elevated early in diabetes but increased further when 
inflammation peaked at 8 months of age. 
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Table 1. Inflammatory pathways activated by diabetes based on ingenuity analysis. 
Columns show the number of genes altered with FDR< 5% by SAM at each age. 
Pathway name (number of genes in pathway) 2m 4m 8m P value at 8m 
Leukocyte Extravasation signaling (191 genes) 0 16 80 4.99E-14 
NF-kB Signaling (143 genes) 3 0 61 7.6SE-ll 
IL-4 signaling (68 genes) 4 7 33 1.24E-08 
IL-2 signaling (S3 genes) 0 3 24 l.71E-OS 
IL-6 signaling (91 genes) 0 3 29 3.0SE-03 
Complement system (36 genes) 2 3 12 7.8SE-03 
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Table 2. Pro-inflammatory genes up-regulated at least 1.5 fold in 8 month diabetic 
kidney 
Gene Title Gene Symbol p-value fold change 
TNF & receptor 
tumor necrosis factor receptor superfamily, member 1 b Tnfrsf1 b 2. 32E-04 1.89 
tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 2.35E-03 2.53 
tumor necrosis factor, alpha-induced protein 3 Tnfaip3 2.31 E-03 2.00 
tumor necrosis factor (ligand) superfamily, member 13b Tnfsf13b 2.36E-02 1.70 
Interleukin family 
interleukin 1 family, member 6 111f6 9.19E-03 2.58 
TLRs 
toll-like receptor 1 Tlr1 1.94E-03 1.86 
toll-like receptor 13 Tlr13 7.06E-03 1.60 
toll-like receptor 2 Tlr2 2.13E-02 1.99 
toll-like receptor 4 Tlr4 5.05E-02 1.64 
chemokine 
chemokine (C-C motif) ligand 7 Ccl7 2.00E-03 1.52 
chemokine (C-C motif) ligand 12 Ccl12 5.50E-03 5.48 
chemokine (C-C motif) ligand 2 Ccl2 9.65E-03 4.25 
chemokine (C-C motif) ligand 5 Ccl5 1.49E-02 3.36 
chemokine (C-C motif) ligand 9 Ccl9 1.89E-02 3.83 
chemokine (C-C motif) ligand 6 Ccl6 2. 77E-02 3.36 
chemokine (C-C motif) ligand 8 Ccl8 3.69E-02 3.33 
chemokine (C-X-C motif) ligand 11 Cxcl11 2. 38E-04 2.99 
chemokine (C-X-C motif) ligand 16 Cxcl16 6.09E-04 1.89 
chemokine (C-X-C motif) ligand 10 Cxcl10 5.05E-04 3.81 
chemokine (C-X-C motif) ligand 2 Cxcl2 1.03E-02 3.41 
chemokine (C-X-C motif) ligand 13 Cxcl13 1.58E-02 2.45 
chemokine (C-X-C motif) ligand 1 Cxcl1 1.35E-02 2.65 
Adhesion molecules 
intercellular adhesion molecule Icam1 7.21E-03 2.04 
vascular cell adhesion molecule 1 Vcam1 4.98E-03 4.58 
CD44 antigen Cd44 1.02E-02 8.01 
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Table 3. Fold change in fat metabolism mRNA expression 
Gene Gene metabolic OVE26/FVB Symbol functions 
SREBP1 Fatty acid synthesis O.53±O.O4 
FASN Fatty acid synthesis O.49±O.O5 
L-PK Fatty acid synthesis 1.12±O.O3 
ACC Fatty acid synthesis O.64±O.O4 
PPAR-o Fatty acid oxidation 1.0B±O.13 
PPAR-~ Fatty acid oxidation O.9B±O.04 
ACO Fatty acid oxidation O.91±O.OB 
SREBP2 Cholesterol synthesis O.B6±O.04 
HMGCR Cholesterol synthesis O.71±O.O4 
ABCA1 Cholesterol efflux 1.02±O.15 
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A Estimated prevalence of diagnosed and 
undiagnosed diabetes In people aged 20 years or 
older, by age group, United States, 2007 
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Figure 9: Diabetes Statistics. A) Estimated prevalence of diagnosed and undiagnosed 
diabetes in people aged 20 years or older, by age group, United States, 2007; B) 
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Figure 10. Developmental changes in albuminuria and gene expressions: Panel A 
shows the increase in 24hr urine albumin excretion in female OVE26 mice with age. At 
each age diabetic albuminuria was greater than the next youngest group (P<O.Ol by 
ANOVA) and greater than control mice of the same age (P<0.05 by T-test). (Values are 
the means ± SE of 6 or more mice for each age group). Panel B shows the number of 
genes significantly up or down-regulated in OVE26 mice at each age. Results were 
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Figure 11: Top 10 biological functions and/or diseases altered by both age and 
diabetes: Three of the top five top biological functions identified by Ingenuity are 
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Figure 12: Expression of inflammatory response genes identified by Ingenuity 
online database increased by age in diabetic kidneys: Gray bar stands for 
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Figure 13. Complement component 3 (C3) mRNA and protein are up-regulated in 
diabetic mouse kidney. A) e3 mRNA is increased in diabetic mice at all ages based on 
Affymetrix array results. Y axis shows the fold change of OVE26 over FVB (P<O.002 
for each age by T-test). Microarray results were validated by real-time peR at 4 months 
(B) and 8 months (C). Immunofluorescent staining of e3 on sections of (D) diabetic or 
(G) control kidneys. Dual labeling for albumin on the same sections is shown in Panels 
E and H. Merged pictures of both stains are shown in panels F and I for diabetic and 
control kidneys, respectively. Original magnification X400. In situ hybridization shows 
e3 mRNA in tubular cells of diabetic mouse. J) Kidney from 8 month old control FVB 
mouse showed weak staining. K) Kidney from an age-matched OVE26 mouse showed 
positive (dark blue) staining in many tubules. Serial sections of OVE26 kidney reveal 
the strongest e3 hybridization (L lower arrow) in a tubule that stained strongly for 
albumin (M lower arrow). The upper arrows in panels Land M point to a common 
glomerulus used for aligning the sections. Original magnification X200. 
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Figure 14. Increased VCAMI expression in 8 month old diabetic kidney. A) 
VCAM 1 RNA expression level is up-regulated by diabetes only at 8 months of age 
according to microarray results. Y axis shows the fold increase of OVE26 relative to 
FVB. The asterisk indicates that VCAMI elevation is significant at that age (P<O.Ol, 
T-test). B) Pearson correlation analysis ofVCAMl gene array signal versus 24 hour 
urinary albumin excretion (R2=0.933, P<O.Ol). Immunohistochemical staining of 
VCAMI on paraffin sections ofC) control or D) diabetic kidney. Panels E and F show 
serial sections of diabetic kidney stained for albumin (green) or for VCAMI (red). The 
white arrows indicate landmarks that allow rapid visual alignment of the serial sections. 
The staining shows that OVE26 tubules that stain strongly for VCAM 1 do not stain 
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Figure 15. Increased CD44 expression in 8 month old diabetic kidney. A) 
Microarray results show that CD44 mRNA levels are up-regulated significantly only at 8 
months of age. The asterisk indicates that the elevation of gene expression level is 
significant (P<O.OOOl, t-test) between control and diabetic 8 month old mice. B) 
Correlation analysis of CD44 expression versus albuminuria in diabetic 8 month mice 
(Pearson correlation coefficient=O.982, P<O.0005). Immunohistochemical staining for 
CD44 on sections of FVB (C) or diabetic kidney with moderate (D) or severe (E,F) 
albuminuria. Panels G (albumin) and H (CD44) show that many tubules, especially 
dilated tubules, stain for both albumin and CD44. All original magnification X200 
except F, X400 
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Figure 16. Increased CD68 expression and macrophage infiltration in 8 month 
diabetic kidney. A) Gene array results show that the macrophage marker CD68 mRNA 
increased significantly in 8 month diabetic kidney. Asterisk indicates that the elevation 
of gene expression level is significant (P<O.O I, t-test) at that age. B) Correlation 
analysis ofCD68 expression and 24 hour urine albumin excretion (R2=O.965, P<O.005). 
C) Immunofluorescent staining of macrophage with F4/80 antibody (red) on 
tubulointerstitial area of 8 month diabetic kidney section merged with albumin staining 
on the same section (green). D) FVB sections presented no staining of macrophage. 
Original magnification X400. 
84 
85 
Figure 17. CD44 and VCAMI are induced in different OVE26 tubules. Kidney 
sections from 8 month old OVE26 mice were stained for the indicated antigens in panels 










< . .. 
< . 
"" u ... 2 
~ 


































Figure 18. Increased CYP27B1 expression in diabetic mouse kidney and increased 
serum level of 1,25-dihydroxy vitamin D in diabetic mouse. A) CYP27Bl mRNA is 
increased in diabetic mouse kidney at all ages based on Affymetrix array results. Y axis 
indicates the fold change ofOVE26 over FVB (P.:sO.OI at each age by t-test). B) Serum 
1,25-dihydroxy vitamin D levels are elevated (P< 0.005) in 8 month old diabetic mice. 
Immunohistochemical staining ofCYP27BI on paraffin sections ofC) control and D) 
diabetic kidney. Original magnification X200. E) Serum calcium level is slightly 
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Figure 19. Fasn microarray results were validated by rtPeR using average fold 
change (OVE26 over FVB). Red column represents microarray results and green 
column represents rtPCR results. Comparison were made between OVE26 mice and 
FVB mice. 
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Figure 20. SREBFl regulated genes with significantly altered gene expression in 
OVE26 kidney. Green symbols and solid arrows indicate that expression was 
down-regulated in OVE26 mice and that SREBFI normally stimulates expression of that 
gene. Red symbols and dashed arrows indicate that expression was up-regulated in 

























Figure 21. Increased inflammatory genes expression at different stage of diabetes in 
OVE26 mice. At early stage of diabetes, hyperglycemia can induce moderate protein 
leakage, which may stimulate C3 expression. As the disease progressed, C3 expression 
was further increased possibly regulated by elevated pro-inflammatory cytokines 
expressIOn. At late stage of diabetes, inflammatory genes CD44 and VCAMI were 
up-regulated, which were associated with excessive protein leakage. The severe protein 
leakage may also promote macrophage infiltration and activate Nf-kB transcriptional 
pathway. The latter may contribute to elevated VCAM-I expression in the tubules. 
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